Healthy aging: Molecular bases for the development of a bioinnovative food prototype with psychobiotics

CATALDO PG; BULACIOS GA; NAJA J; ELEAN MD; POSSE DE CHAVES E; TARANTO MP; BEAUQUIS J; HEBERT EM; SAAVEDRA L

Denver

Congreso; ISAPP 2023 Annual Meeting; 2023

International Scientific Association for Probiotics ans Prebiotics

One consequence of the increase in longevity is the appearance of diseases associated with aging such as dementia. Alzheimer's disease (AD) is the most common type of dementia. Currently, there is no definitive treatment for AD, cholinesterase inhibitors and memantine are the current mainstays of the treatment. Numerous nutritional interventions for AD are currently under study. To date, there is scientific evidence on the use of psychobiotics, those probiotics that provide a potential benefit to mental health. This workrepresents the first report on the daily oral administration (30 days) of Lactobacillus delbrueckii subsp. lactis CRL 581 (1x10E8), an in vitro AChE inhibitor and Levilactobacillus brevis CRL 2013 (1x 10E9), a GABA producerstrain, on oxidative stress and cholinergic dysfunction in a scopolamine-mice model. Scopolamine, a cholinergic receptor blocker, produced memory loss, cognitive impairment and increased AChE activity, mimicking those alterations observed in AD. Administration of CRL581 showed a decrease in AChE activity in brain homogenates of scopolamine-treated mice; CRL2013 increased catalase activity and the amount of reduced glutathione. In addition, both strains were able to reduce malondialdehyde, an end-product of lipid peroxidation, considered to be one of the markers of reactive oxygen species generation. Shot-gun proteomic analysis of scopolamine- and psychobiotics-brain homogenates revealed unique differential expression patterns. Our results show that both strains evaluated here ameliorate oxidative stress markers in a scopolamine-mice model supporting the development of a functional supplement containing genetically and functionally characterized psychobiotics for non-pharmacological intervention of those affected with AD.